Skip to content

Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control

Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02658591
Enrollment
60
Registered
2016-01-20
Start date
2016-01-31
Completion date
2024-05-31
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Obesity

Keywords

Food intake, Satiety, Appetite, Glycemia, Faba bean, Protein, Snack

Brief summary

The investigators hypothesized that consuming crackers or pasta enriched with faba bean fractions (faba bean protein concentrate, faba bean protein isolate, faba bean flour and faba bean starch), would reduce the blood glucose response to the meal compared to foods without faba bean components and reduce food intake at a meal

Interventions

DIETARY_SUPPLEMENTCrackers/pasta with added faba bean protein concentrate

Protein concentrate treatment

DIETARY_SUPPLEMENTCrackers/pasta with added faba bean protein isolate

Protein isolate treatment

DIETARY_SUPPLEMENTCrackers/pasta with added faba bean starch

Starch treatment

DIETARY_SUPPLEMENTCrackers/pasta with added faba bean flour

Flour treatment

DIETARY_SUPPLEMENTCrackers/pasta with no faba bean fraction

Control treatment

Sponsors

University of Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Non-smoking * No metabolic disease * BMI 20 - 25 kg/m\^2 * Male * Age 18-30

Exclusion criteria

* Intolerance to treatments * Currently taking appetite-modifying medications * Restrictive eating * Smoking * Over- or underweight * Breakfast-skipping

Design outcomes

Primary

MeasureTime frameDescription
Change in blood glucose levelsStarting at the beginning of each session (0 minutes, before consumption of treatment) and every 15 - 30 minutes up to 200 minutes (time of completion of each session)Each participant will attend 5 sessions in total (randomized 5-arm cross-over design)
Change in gut hormone levels measured in the bloodStarting at the beginning of each session (0 minutes, before consumption of treatment) and every 30 minutes up to 200 minutes (time of completion of each session)Each participant will attend 5 sessions in total (randomized 5-arm cross-over design)

Secondary

MeasureTime frameDescription
Subjective appetiteFrom 0 to 200 minutesMeasured using Visual Analog Scales (VAS)
Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period120 minutes after completion of treatment, 20 minutes were allocated to allow for pizza consumptionEach participant will also answer questions related to physical comfort, motivation to eat, and rating feelings of energy and fatigue using Visual Analog Scales (VAS)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026